Allogene Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:ALLO) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -115.09 M-184.81 M-220.52 M-237.73 M-200.3 M-149.25 M -109.23 M Cash from investing activities -505.12 M163.66 M106.16 M163.29 M75.69 M95.56 M 59.8 M Cash from financing activities 633.59 M11.96 M2.95 M95.69 M116.67 M30.16 M 37.29 M Free cash flow -115.09 M-184.81 M-220.52 M-237.73 M-200.3 M-149.63 M -109.53 M

News

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

Allogene Therapeutics Q1 2026 Earnings Call Transcript - Allogene Therapeutics (NASDAQ:ALLO)

Legend Biotech: Undervalued Leader In The CAR-T Race (NASDAQ:LEGN)

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Company News for Apr 14, 2026

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow (NASDAQ:ALLO) 2026-04-14

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Citizens reiterates Allogene stock rating on pipeline progress

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript